PL3229843T3 - Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji - Google Patents
Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycjiInfo
- Publication number
- PL3229843T3 PL3229843T3 PL15801384T PL15801384T PL3229843T3 PL 3229843 T3 PL3229843 T3 PL 3229843T3 PL 15801384 T PL15801384 T PL 15801384T PL 15801384 T PL15801384 T PL 15801384T PL 3229843 T3 PL3229843 T3 PL 3229843T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306871 | 2014-11-25 | ||
| EP15801384.7A EP3229843B1 (en) | 2014-11-25 | 2015-11-24 | Pharmaceutical composition, preparation and uses thereof |
| PCT/EP2015/077423 WO2016083331A1 (en) | 2014-11-25 | 2015-11-24 | Pharmaceutical composition, preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3229843T3 true PL3229843T3 (pl) | 2020-06-29 |
Family
ID=52013979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15801384T PL3229843T3 (pl) | 2014-11-25 | 2015-11-24 | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170258937A1 (pl) |
| EP (1) | EP3229843B1 (pl) |
| JP (1) | JP6722688B2 (pl) |
| AR (1) | AR102778A1 (pl) |
| DK (1) | DK3229843T3 (pl) |
| ES (1) | ES2774365T3 (pl) |
| LT (1) | LT3229843T (pl) |
| PL (1) | PL3229843T3 (pl) |
| PT (1) | PT3229843T (pl) |
| TW (1) | TW201628644A (pl) |
| WO (1) | WO2016083331A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014273043B2 (en) | 2013-05-30 | 2019-02-07 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| PL3223796T3 (pl) | 2014-11-25 | 2021-12-20 | Curadigm Sas | Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania |
| AU2015352685B2 (en) | 2014-11-25 | 2020-09-17 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| FI3229776T3 (fi) | 2014-11-25 | 2023-08-15 | Curadigm Sas | Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt |
| UA124572C2 (uk) | 2015-05-28 | 2021-10-13 | Нанобіотікс | Наночастинки для застосування як терапевтичної вакцини |
| CN117042807A (zh) * | 2020-11-30 | 2023-11-10 | 安必圣有限责任公司 | 用抗体片段修饰且装载有细胞毒性药的多特异性人类白蛋白纳米颗粒 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT75469A (en) * | 1994-02-28 | 1997-05-28 | Medinova Med Consulting Gmbh | Drug targeting system, method for preparing same and its use |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| RU2006101216A (ru) * | 2003-08-01 | 2007-07-20 | Амген Инк. (US) | Кристаллические полипептиды 2 фактора некроза опухолей |
| ES2531732T3 (es) | 2003-12-22 | 2015-03-18 | Bracco Suisse Sa | Montaje de microvesícula rellena de gas para imagenología de contraste |
| WO2007122956A1 (ja) | 2006-03-24 | 2007-11-01 | Toto Ltd. | 酸化チタン複合体粒子、その分散液、およびそれらの製造方法 |
| AU2007247770B2 (en) | 2006-05-04 | 2013-07-18 | Reformpharm Pty Ltd | Drug release from nanoparticle-coated capsules |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| WO2009105774A2 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| US20130023714A1 (en) * | 2008-10-26 | 2013-01-24 | Board Of Regents, The University Of Texas Systems | Medical and Imaging Nanoclusters |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| CN102781472B (zh) | 2010-02-17 | 2014-07-02 | 国立大学法人神户大学 | 放射线治疗剂 |
| KR101786142B1 (ko) * | 2010-03-26 | 2017-10-17 | 아브락시스 바이오사이언스, 엘엘씨 | 간세포 암종의 치료 방법 |
| US9782342B2 (en) * | 2010-10-11 | 2017-10-10 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| WO2012104277A2 (en) | 2011-01-31 | 2012-08-09 | Nanobiotix | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles. |
| JP6158714B2 (ja) | 2011-01-31 | 2017-07-05 | ナノビオティックスNanobiotix | ナノ粒子デリバリーシステム、その製造および使用 |
| JP2015515462A (ja) * | 2012-03-20 | 2015-05-28 | イェシバ・ユニバーシティYeshiva University | 輸血の有効性を高める方法 |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140213765A1 (en) | 2013-01-25 | 2014-07-31 | I-Liang Lee | Albumin tissue scaffold |
| AU2014273043B2 (en) * | 2013-05-30 | 2019-02-07 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| JP2018500298A (ja) | 2014-11-25 | 2018-01-11 | ナノビオティックスNanobiotix | 医薬組成物、その調製及び使用 |
| PL3223796T3 (pl) | 2014-11-25 | 2021-12-20 | Curadigm Sas | Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania |
| AU2015352685B2 (en) | 2014-11-25 | 2020-09-17 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| FI3229776T3 (fi) | 2014-11-25 | 2023-08-15 | Curadigm Sas | Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt |
-
2015
- 2015-11-24 LT LTEP15801384.7T patent/LT3229843T/lt unknown
- 2015-11-24 PT PT158013847T patent/PT3229843T/pt unknown
- 2015-11-24 ES ES15801384T patent/ES2774365T3/es active Active
- 2015-11-24 AR ARP150103846A patent/AR102778A1/es unknown
- 2015-11-24 WO PCT/EP2015/077423 patent/WO2016083331A1/en not_active Ceased
- 2015-11-24 EP EP15801384.7A patent/EP3229843B1/en active Active
- 2015-11-24 PL PL15801384T patent/PL3229843T3/pl unknown
- 2015-11-24 TW TW104139007A patent/TW201628644A/zh unknown
- 2015-11-24 DK DK15801384.7T patent/DK3229843T3/da active
- 2015-11-24 US US15/529,096 patent/US20170258937A1/en not_active Abandoned
- 2015-11-24 JP JP2017546030A patent/JP6722688B2/ja active Active
-
2018
- 2018-08-01 US US16/051,604 patent/US11191846B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR102778A1 (es) | 2017-03-22 |
| US20170258937A1 (en) | 2017-09-14 |
| WO2016083331A1 (en) | 2016-06-02 |
| JP6722688B2 (ja) | 2020-07-15 |
| LT3229843T (lt) | 2020-05-25 |
| TW201628644A (zh) | 2016-08-16 |
| DK3229843T3 (da) | 2020-03-09 |
| US20180339062A1 (en) | 2018-11-29 |
| US11191846B2 (en) | 2021-12-07 |
| EP3229843A1 (en) | 2017-10-18 |
| JP2017538782A (ja) | 2017-12-28 |
| EP3229843B1 (en) | 2020-01-01 |
| ES2774365T3 (es) | 2020-07-20 |
| PT3229843T (pt) | 2020-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276695B (en) | Antibodies, pharmaceutical preparations and their uses | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| GB201409471D0 (en) | Pharmaceutical composition | |
| PT3223796T (pt) | Composições farmacêuticas, preparação e suas utilizações | |
| GB201409488D0 (en) | Pharmaceutical composition | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| GB201409485D0 (en) | Pharmaceutical composition | |
| ZA201703398B (en) | Pharmaceutical composition and methods | |
| PT3229843T (pt) | Composição farmacêutica, a sua preparação e as suas utilizações | |
| ZA201502073B (en) | Pharmaceutical composition | |
| IL262929B1 (en) | Preparations for treatment, methods of their preparation and their uses | |
| ZA201508726B (en) | Pharmaceutical composition | |
| SMT202000391T1 (it) | Composizione farmaceutica | |
| IL249073A0 (en) | Cytin-glucan complex, its preparation and uses | |
| SG10201504332VA (en) | Pharmaceutical Composition | |
| GB2509426B (en) | Clomazone composition, its preparation and use thereof | |
| HK40115817A (en) | Pharmaceutical composition, preparation and uses thereof | |
| IL284405A (en) | Pharmaceutical composition, preparation and uses thereof | |
| TH1501007100A (th) | องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน |